Background
The incidence of hepatocellular carcinoma is increasing. Most patients are identified at advanced stages, where survival is measured in a matter of months.
From 2015 to 2018, the first period under study, the only approved molecularly targeted systemic therapy for advanced hepatocellular carcinoma was the tyrosine kinase inhibitor sorafenib. ...
